{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:39:04Z","timestamp":1771591144724,"version":"3.50.1"},"reference-count":58,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014089","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T12:03:10Z","timestamp":1699272190000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon"],"prefix":"10.1002","volume":"2025","author":[{"given":"Nancy","family":"Maltez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; The Ottawa Hospital; Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara J","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Cochrane Musculoskeletal; Faculty of Medicine, University of Ottawa; Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadumo","family":"Rirash","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Western Ontario; London Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Tanjong Ghogomu","sequence":"additional","affiliation":[{"name":"Bruy\u00e8re Research Institute; University of Ottawa; Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E","family":"Harding","sequence":"additional","affiliation":[{"name":"Pediatric Critical Care Medicine; SUNY Upstate Medical University; Syracuse USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C","family":"Tingey","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Western Ontario; London Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health; University of Ottawa; Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine; University of Ottawa; Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology and Biostatistics; University of Western Ontario; London Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"10.1002\/14651858.CD014089-BIB0001|cit1","first-page":"2086","article-title":"Efficacy of Tadalafil in Raynaud\u2019s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study","volume":"62 Suppl 10","author":"Agarwal","year":"2010","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD014089-BIB0002|cit2","unstructured":"Andrigueti FV Ebbing PC Arismendi MI Kayser C Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA)"},{"key":"10.1002\/14651858.CD014089-BIB0003|cit3","first-page":"S151","article-title":"Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study","volume":"35 Suppl 106","author":"Andrigueti","year":"2017","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"15","key":"10.1002\/14651858.CD014089-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinternmed.2012.2271","article-title":"Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study","volume":"172","author":"Caglayan","year":"2012","journal-title":"Archives of International Medicine"},{"key":"10.1002\/14651858.CD014089-BIB0005|cit5","unstructured":"Caglayan E Axmann S Huntgeburth M Erdmann E Rosenkranz S Vardenafil in patients with raynaud's syndrome European Society of Cardiology and ESC Congress. Paris, France 2011 655"},{"key":"10.1002\/14651858.CD014089-BIB0006|cit6","unstructured":"Caglayan E Axmann S Huntgeburth M Erdmann E Rosenkranz S Hellmich M Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial American Heart Association's Scientific Sessions: Orlando and FL United States 2011 https:\/\/www.ahajournals.org\/browse\/toc\/circ\/124\/suppl_21\/meeting abstract-long-toc\/b5331"},{"issue":"19","key":"10.1002\/14651858.CD014089-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014089-BIB0008|cit8","unstructured":"Herrick AL Van Den Hoogen F Gabrielli A Tamimi N Reid C O'Connell D Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR\/ARHP 09. Atlanta and GA United States 2009 472"},{"issue":"3","key":"10.1002\/14651858.CD014089-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","article-title":"Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD014089-BIB0010|cit10","unstructured":"Laumann A Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data) www.clinicaltrials.gov\/ct2\/show\/NCT00822354"},{"key":"10.1002\/14651858.CD014089-BIB0011|cit11","unstructured":"A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon www.clinicaltrials.gov\/ct2\/show\/NCT01090492 2018"},{"issue":"10","key":"10.1002\/14651858.CD014089-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3899\/jrheum.090270","article-title":"Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis","volume":"36","author":"Schiopu","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD014089-BIB0013|cit13","unstructured":"Shenoy P Agarwal V Misra R Kumar S Choudhary S Jha L Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom 2009 i.26 OP77"},{"issue":"12","key":"10.1002\/14651858.CD014089-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD014089-BIB0015|cit15","unstructured":"Bellando-Randone S Miniati I Guiducci S Letizia CM Blagojevic J Fiori G Sildenafil increases vasodilation in systemic sclerosis: an interim analysis from a single centre pilot study [abstract #593] Arthritis and Rheumatology 2010 S248"},{"issue":"4","key":"10.1002\/14651858.CD014089-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/sj.clpt.6100103","article-title":"The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon","volume":"81","author":"Friedman","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD014089-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Park JK Lee EY Yoon MJ Kim YK Park CS Giles JT Head to head comparison of Udenafil versus Amlodipine in the treatment of secondary Raynaud's phenomenon in the treatment of secondary Raynaud's Phenomenon: a double-blind, randomized cross-over study Scientific Abstracts 2013","DOI":"10.1136\/annrheumdis-2013-eular.244"},{"key":"10.1002\/14651858.CD014089-BIB0018|cit18","unstructured":"Cracowski JL Roustit M Mouhib M Lotito A Khouri C On demand sildenafl as a treatment of raynaud's phenomenon: A series of N-of-1 trials 2nd Joint Meeting of the European Society for Microcirculation, ESM and European Vascular Biology Organisation and EVBO. Geneva Switzerland 2017 11"},{"issue":"4","key":"10.1002\/14651858.CD014089-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"JC21","DOI":"10.7326\/ACPJ201902190-021","article-title":"In Raynaud phenomenon, on-demand sildenafil did not reduce disability or frequency or duration of attacks","volume":"170","author":"Mirza","journal-title":"Annals of Internal Medicine, ACP Journal Club"},{"key":"10.1002\/14651858.CD014089-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Roustit M Cracowski JL Giai J Subtil F Gaget O Mouhib M On-demand sildenafil as a treatment for raynaud's phenomenon: A series of N-of-1 trials. 5th Systemic Sclerosis World Congress. Bordeaux France 2018 175 176","DOI":"10.1016\/j.clinthera.2017.05.015"},{"key":"10.1002\/14651858.CD014089-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Roustit M Gaget O Mouhib M Khouri C On demand sildenafil as a treatment of raynaud's phenomenon: A series of n-of-1 trials 13th Congress of the European Association for Clinical Pharmacology and Therapeutics and EACPT 2017. Prague Czechia 2017 e4","DOI":"10.1016\/j.clinthera.2017.05.015"},{"issue":"10","key":"10.1002\/14651858.CD014089-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"694","DOI":"10.7326\/M18-0517","article-title":"On-demand Sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials","volume":"169","author":"Roustit","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD014089-BIB0023|cit23","unstructured":"Roustit M Giai J Gaget O Khouri C Mouhib M Lotito A On-demand Sildenafil as a treatment of Raynaud's phenomenon: a series of N-of-1 trials (abstract # CO-51) Annual Meeting of French Society of Pharmacology and Therapeutics, and INSERM Clinical Research Centers, CIC Meeting Rouen, France 16"},{"key":"10.1002\/14651858.CD014089-BIB0024|cit24","unstructured":"Watanabe H Nishio S Ohmae E Sildenafil improves fore arm blood flow in patients with Raynaud\u2019s phenomenon (abstract P1207) European Heart Journal 2004 202"},{"key":"10.1002\/14651858.CD014089-BIB0025|cit25","unstructured":"A randomised, double blind, placebo-controlled, cross-over pilot study to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days in patients with secondary Raynaud's disease https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2007-000397-23 (first received May 29, 2007)"},{"key":"10.1002\/14651858.CD014089-BIB0026|cit26","unstructured":"Safety, tolerability, and pharmacodynamic profile of oral 2101 in secondary Raynaud's disease clinicaltrials.gov\/ct2\/show\/NCT00528242"},{"key":"10.1002\/14651858.CD014089-BIB0027|cit27","unstructured":"Trial of IC351 in female scleroderma patients with Raynaud's and sexual dysfunction clinicaltrials.gov\/ct2\/show\/NCT00707187"},{"key":"10.1002\/14651858.CD014089-BIB0028|cit28","first-page":"484\u20135","article-title":"Double-blind, placebo-controlled trial of Sildenafil for the management of primary Raynaud's phenomenon (Abstract SAT0342)","volume":"63 Suppl 1","author":"Zamiri","year":"2004","journal-title":"Annals of Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD014089-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1024\/0301-1526\/a000661","article-title":"ESVM guidelines - the diagnosis and management of Raynaud's phenomenon","volume":"46","author":"Belch","year":"2017","journal-title":"VASA - European Journal of Vascular Medicine"},{"key":"10.1002\/14651858.CD014089-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"l4378","DOI":"10.1136\/bmj.l4378","article-title":"CONSORT 2010 statement: extension to randomised crossover trials","volume":"366","author":"Dwan","year":"2019","journal-title":"BMJ"},{"issue":"907","key":"10.1002\/14651858.CD014089-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(97)02419-7","article-title":"Language bias in randomised controlled trials published in English and German","volume":"350","author":"Egger","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD014089-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.autrev.2008.07.002","article-title":"Treatment of Raynaud's phenomenon","volume":"8","author":"Garc\u00eda-Carrasco","year":"2008","journal-title":"Autoimmunity Reviews"},{"key":"10.1002\/14651858.CD014089-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1136\/bmj.e289","article-title":"Diagnosis and management of Raynaud\u2019s phenomenon","volume":"344","author":"Goundry","year":"2012","journal-title":"BMJ"},{"issue":"7653","key":"10.1002\/14651858.CD014089-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations","volume":"336","author":"Grading Working Group","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014089-BIB0035|cit35","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD014089-BIB0036|cit36","first-page":"87","article-title":"Medical treatment in Raynaud's disease","volume":"465","author":"Hansteen","year":"1976","journal-title":"Acta Chirurgica Scandinavica. Supplementum"},{"issue":"5","key":"10.1002\/14651858.CD014089-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/rheumatology\/keh552","article-title":"Pathogenesis of Raynaud's phenomenon","volume":"44","author":"Herrick","year":"2005","journal-title":"Rheumatology"},{"issue":"7414","key":"10.1002\/14651858.CD014089-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014089-BIB0039|cit39","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cohrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD014089-BIB0040|cit40","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook\/"},{"key":"10.1002\/14651858.CD014089-BIB0041|cit41","unstructured":"Higgins JPT Li T Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014089-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"392542","DOI":"10.1155\/2011\/392542","article-title":"PDE5i in scleroderma Raynaud phenomenon and digital ulcers: current status of clinical trials","volume":"2011","author":"Impens","year":"2011","journal-title":"International Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD014089-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD014089-BIB0044|cit44","unstructured":"Lefebvre C Manheimer M Glanville J on behalf of the Cochrane Information Retrieval Methods Group Chapter 6: Searching for studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD014089-BIB0045|cit45","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD014089-BIB0046|cit46","first-page":"485","article-title":"Raynaud's phenomenon: a prosposal for classification","volume":"10","author":"LeRoy","year":"1992","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD014089-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/VHRM.S4551","article-title":"Advances in the treatment of Raynaud's phenomenon","volume":"24","author":"Levien","year":"2010","journal-title":"Vascular Health and Risk Management"},{"issue":"5","key":"10.1002\/14651858.CD014089-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"ACR Preliminary criteria for the classification of systemic sclerosis (scleroderma): Special article","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD014089-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-4939-1526-2_3","volume-title":"Raynaud's Phenomenon","author":"Maundrell","year":"2015"},{"issue":"9","key":"10.1002\/14651858.CD014089-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD014089-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.1989.tb07791.x","article-title":"Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial","volume":"120","author":"Ortonne","year":"1989","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD014089-BIB0052|cit52","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"12","key":"10.1002\/14651858.CD014089-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000467.pub2","article-title":"Calcium channel blockers for primary and secondary Raynaud's phenomenon","author":"Rirash","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD014089-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Annals of Rheumatic Disease"},{"key":"10.1002\/14651858.CD014089-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014089-BIB0056|cit56","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Akl E on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017) Available from: www.training.cochrane.org\/handbook"},{"issue":"13","key":"10.1002\/14651858.CD014089-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","article-title":"Raynaud's Phenomenon","volume":"347","author":"Wigley","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014089-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011813.pub2","article-title":"Drug interventions versus placebo for the treatment of Raynaud\u2019s phenomenon: generic protocol","author":"Rirash","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T09:48:08Z","timestamp":1738835288000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014089"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014089","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]}}}